• PYC is developing two investigational drug candidates for blinding eye diseases of childhood: VP-001 for Retinitis Pigmentosa type 11 (RP11) and PYC-001 for Autosomal Dominant Optic Atrophy (ADOA)
• Data from the ongoing Phase 1/2 trials of VP-001 and PYC-001 will be presented at the ARVO conference
• The presentations will highlight the safety/tolerability and emerging efficacy profiles of both drug candidates

PYC Therapeutics is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available. The company currently has three clinical-stage drug development programs, including two drug candidates that address the underlying cause of blinding eye diseases of childhood: VP-001 for Retinitis Pigmentosa type 11 (RP11) and PYC-001 for Autosomal Dominant Optic Atrophy (ADOA). Both drug candidates are the most advanced assets in clinical development for their respective target diseases and hold first-in-indication potential.PYC today announces that data from the ongoing Phase 1/2 trials of both VP-001 and PYC-001 in RP11 and ADOA respectively will be presented at the Association for Research in Vision and Ophthalmology (ARVO) conference in Denver, Colorado between 3 and 7 May 2026. The presentations will highlight the safety/tolerability and emerging efficacy profiles of both drug candidates established in the clinical trials completed to date.The presentations will cover the following:- Dr. Patrick Yu-Wai-Man: SUNDEW: A Phase 1A Single Ascending Dose (SAD) Study to Evaluate the Safety and Tolerability of PYC-001 to Treat OPA1-Associated ADOA- Dr. Jessica Morgan: Adaptive optics imaging, microperimetry and optoretinography following intravitreal injection of VP-001 in patients with PRPF31-associated RP- Dr. Fred Chen: A Phase 1B Multiple Ascending Dose Study of VP-001 for PRPF31-related RP- Dr. Patrick Yu-Wai-Man: Innovative Therapies for Inherited Optic Neuropathies